Search PubMed⌕ Search

Biomedical subjects

M R Taylor

Publications and source records attributed to M R Taylor.

At least 91 records · Page 5Linked to original sources
PubMed1970

Transport of sick newborn babies.

When sick newborn babies are transferred to Hammersmith Hospital they are collected from the referring hospital or from home by a paediatric resident doctor and a nurse. They prepare the baby for the journey by giving any urgent treatment required, for procedures are difficult to carry out in a moving ambulance. Babies who are likely to become apnoeic are intubated before transport so that ventilation can be started immediately if required. The baby travels in a portable incubator, and special attention is paid to prevention of hypothermia, adequate oxygenation, and respiration. Altogether 122 babies were transferred in 1969, the main reasons being prematurity, hyaline membrane disease, and apnoeic attacks. Five improved during the journey, 102 did not change significantly and 15 became worse. There was no evidence that travel per se harmed any of the babies, though in a few cases deterioration might have been prevented had observation and treatment been easier in the ambulance. Fifty-eight (47%) of the babies eventually died, but the group was a highly selected one with a high proportion of small, immature, and ill babies. We conclude that for very ill newborn babies the advantages of transfer to an intensive care unit probably outweigh the disadvantages of transport, provided that the precautions described here are taken.

Acidosis↗
PubMedDate not supplied

Pharmacokinetic and dose tolerability study of ADD 94057 in comedicated patients with partial seizures.

ADD 94057, a metabolite of fluzinamide, manufactured by the A. H. Robins Company, blocks chemically- and electrically-induced seizures in animals. The primary objective of this open add-on study was to evaluate patient tolerability of ADD 94057 at ascending target plasma concentrations. Nine subjects with medically refractory seizures were receiving phenytoin (PHT, 3), carbamazepine (CBZ, 3), or both (3). A pharmacokinetic profile after a single oral 400-mg dose of ADD 94057 was used to calculate ADD 94057 dosages. After a 4-week baseline period, patients were treated for 4 weeks with weekly ADD 94057 dosage escalations. Two patients completed the study at their assigned highest dosage level; the other patients finished the study at lower dosages. The patients receiving PHT (but not CBZ) tolerated higher plasma concentrations of ADD 94057 than did patients receiving CBZ, alone or in combination with PHT. Adverse experiences included headache, ataxia, blurred vision, diplopia, dizziness, lightheadedness, and mild confusion. Eight of nine patients had reductions in seizure frequency from baseline.

Administration, Oral↗